MHC CLASS-II PRESENTING CELLS ARE NECESSARY FOR THE INDUCTION OF INTRATHYMIC TOLERANCE

被引:27
作者
GOSS, JA [1 ]
NAKAFUSA, Y [1 ]
FLYE, MW [1 ]
DIETHELM, AG [1 ]
FISH, JC [1 ]
KRON [1 ]
MCDONALD [1 ]
机构
[1] WASHINGTON UNIV,SCH MED,DEPT SURG,1 BARNES HOSP PLAZA,SUITE 5108,ST LOUIS,MO 63110
关键词
D O I
10.1097/00000658-199305010-00009
中图分类号
R61 [外科手术学];
学科分类号
摘要
Objective This study determined the form of cellular donor MHC alloantigen necessary for the induction of intrathymic tolerance. Background The authors have achieved indefinite donor-specific tolerance, to a fully MHC-disparate rat heterotopic cardiac allograft, after the pretransplant intrathymic injection of unfractionated donor splenocytes and a single injection of rabbit anti-rat lymphocyte serum (ALS), without subsequent immunosuppression. Methods Male 4-12-week-old Buffalo (RT1b) rats underwent an intrathymic injection of either fractionated Lewis (RT1(1)) red blood cells (purified by Ficoll gradient) or T lymphocytes (purified by nylon wool column and plastic adherence), both of which express only MHC class I alloantigens, or B lymphocytes, macrophages, and dendritic cells (purified by plastic adherence) which express both MHC class I and class II alloantigens. At the completion of alloantigen injection the Buffalo recipient rats were given 1 ml of ALS intraperitoneally. Twenty-one days later a heterotopic Lewis heart was transplanted. Results The intrathymic injection of the fractions of Lewis MHC class I and class II expressing B lymphocytes, macrophages, and dendritic cells induced a donor-specific tolerance that resulted in indefinite Lewis cardiac allograft survival (MST > 125 days) in all recipients without further immunosuppression, whereas groups receiving MHC class I expressing red blood cell or T lymphocyte injections plus ALS rejected Lewis cardiac allografts with a MST of 7.3 and 16.5 days, respectively, thus indicating that the MHC class II expressing cell is necessary for the induction of intrathymic tolerance. Buffalo recipients with a long-term surviving Lewis cardiac allograft, after Lewis MHC class II expressing cells were still able to reject a third-party heterotopic ACI (RT1a) cardiac allograft in normal time (MST = 7.0 days), but did not reject a second Lewis cardiac allograft (MST > 100 days). Additionally, the intrathymic injection of MHC class II expressing cells resulted in decreased Interleukin-2 (IL-2) production and an 80% decrease in in vitro donor-specific cell mediated cytotoxicity, whereas the cytolytic response to a third party was unaltered. Conclusion Donor MHC class II, and not class I, expressing cells are the cells in donor splenocytes, injected intrathymically, responsible for the development of donor-specific allograft tolerance.
引用
收藏
页码:492 / 501
页数:10
相关论文
共 36 条
[1]   CURRENT CONCEPTS - IMMUNOLOGY - TRANSPLANTATION IMMUNOLOGY [J].
BACH, FH ;
SACHS, DH .
NEW ENGLAND JOURNAL OF MEDICINE, 1987, 317 (08) :489-492
[2]   INDUCTION OF CYTO-TOXIC T-CELL PRECURSORS INVIVO - ROLE OF T-HELPER CELLS [J].
BELLGRAU, D .
JOURNAL OF EXPERIMENTAL MEDICINE, 1983, 157 (05) :1505-1515
[3]   H-2 ANTIGENS OF THYMUS DETERMINE LYMPHOCYTE SPECIFICITY [J].
FINK, PJ ;
BEVAN, MJ .
JOURNAL OF EXPERIMENTAL MEDICINE, 1978, 148 (03) :766-775
[4]  
FINK PJ, 1988, ANNU REV IMMUNOL, V6, P115
[5]  
FOKER JE, 1972, ALLOGRAFT REJECTION, P63
[6]   B-CELLS TURN OFF VIRGIN BUT NOT MEMORY T-CELLS [J].
FUCHS, EJ ;
MATZINGER, P .
SCIENCE, 1992, 258 (5085) :1156-1159
[7]   VIRAL DNA IN TRANSFORMED-CELLS .2. STUDY OF SEQUENCES OF ADENOVIRUS-2 DNA IN NINE LINES OF TRANSFORMED RAT CELLS USING SPECIFIC FRAGMENTS OF VIRAL GENOME [J].
GALLIMORE, PH ;
SHARP, PA ;
SAMBROOK, J .
JOURNAL OF MOLECULAR BIOLOGY, 1974, 89 (01) :49-72
[8]  
GOSS JA, 1992, ANN SURG, V216, P223
[9]  
GOSS JA, 1993, IN PRESS TRANSPLANTA
[10]   INDUCTION OF PERIPHERAL TOLERANCE TO CLASS-I MAJOR HISTOCOMPATIBILITY COMPLEX (MHC) ALLOANTIGENS IN ADULT MICE - TRANSFUSED CLASS-I MHC-INCOMPATIBLE SPLENOCYTES VETO CLONAL RESPONSES OF ANTIGEN-REACTIVE LYT-2+ T-CELLS [J].
HEEG, K ;
WAGNER, H .
JOURNAL OF EXPERIMENTAL MEDICINE, 1990, 172 (03) :719-728